CN114807152A - 工程化病毒载体减少了炎症和免疫反应的诱导 - Google Patents

工程化病毒载体减少了炎症和免疫反应的诱导 Download PDF

Info

Publication number
CN114807152A
CN114807152A CN202210208639.3A CN202210208639A CN114807152A CN 114807152 A CN114807152 A CN 114807152A CN 202210208639 A CN202210208639 A CN 202210208639A CN 114807152 A CN114807152 A CN 114807152A
Authority
CN
China
Prior art keywords
seq
nucleic acid
odn
acid sequence
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210208639.3A
Other languages
English (en)
Chinese (zh)
Inventor
陈映恺
G·M·彻尔驰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN114807152A publication Critical patent/CN114807152A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202210208639.3A 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导 Pending CN114807152A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662347302P 2016-06-08 2016-06-08
US62/347,302 2016-06-08
PCT/US2017/036525 WO2017214378A1 (en) 2016-06-08 2017-06-08 Engineered viral vector reduces induction of inflammatory and immune responses
CN201780045910.3A CN109451729B (zh) 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780045910.3A Division CN109451729B (zh) 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导

Publications (1)

Publication Number Publication Date
CN114807152A true CN114807152A (zh) 2022-07-29

Family

ID=60578967

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210208639.3A Pending CN114807152A (zh) 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导
CN201780045910.3A Active CN109451729B (zh) 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780045910.3A Active CN109451729B (zh) 2016-06-08 2017-06-08 工程化病毒载体减少了炎症和免疫反应的诱导

Country Status (7)

Country Link
US (3) US11339396B2 (enExample)
EP (1) EP3468605A4 (enExample)
JP (2) JP7034951B2 (enExample)
KR (1) KR20190017872A (enExample)
CN (2) CN114807152A (enExample)
AU (2) AU2017277647B2 (enExample)
WO (1) WO2017214378A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
JP2021502381A (ja) 2017-11-08 2021-01-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ウイルスベクター誘発性炎症反応を阻害するための組成物および方法
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
WO2020033842A1 (en) 2018-08-10 2020-02-13 Regenxbio Inc. Scalable method for recombinant aav production
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
EP3927723A1 (en) * 2019-02-22 2021-12-29 Life Technologies Corporation Suspension system for adeno associated virus production
WO2020232211A1 (en) * 2019-05-15 2020-11-19 President And Fellows Of Harvard College Compositions and methods for inhibiting nucleic acid vector- induced inflammatory responses
BR112022017735A2 (pt) * 2020-03-05 2022-11-29 Flagship Pioneering Innovations Vi Llc Métodos e composições de supressão de defesa de hospedeiro para modular um genoma
CN115698332A (zh) * 2020-06-12 2023-02-03 新加坡科技研究局 在单细胞水平上评估载体转导效率和/或特异性的方法
EP4301860A1 (en) * 2021-03-04 2024-01-10 Kriya Therapeutics, Inc. Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
WO2025087987A1 (en) * 2023-10-23 2025-05-01 Sartorius Stedim Cellca Gmbh Plasmids for improved aav titers and empty full ratios

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069467A1 (en) * 2006-04-28 2010-03-18 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
CN101712957A (zh) * 2009-11-25 2010-05-26 中国人民解放军第三军医大学第一附属医院 Toll样受体9阻断剂及应用
WO2010108035A1 (en) * 2009-03-18 2010-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for modulating toxic and proinflammatory effects
US20110182927A1 (en) * 1997-06-06 2011-07-28 Eyal Raz Inhibitors of DNA Immunostimulatory Sequence Activity
US20110236392A1 (en) * 2008-09-24 2011-09-29 O'neill Luke Anthony Composition and method for treatment of preterm labor
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
US20140004100A1 (en) * 2010-11-19 2014-01-02 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2014105870A1 (en) * 2012-12-27 2014-07-03 Sierra Sciences, Inc. Enhancing health in mammals using telomerase reverse transcriptase gene therapy
US20150238550A1 (en) * 2012-09-28 2015-08-27 The University Of North Carolina At Chapel Hill AAV Vectors Targeted to Oligodendrocytes
CN105597079A (zh) * 2016-01-11 2016-05-25 中国人民解放军第三军医大学第一附属医院 用于治疗银屑病的药物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7060690B2 (en) 2001-01-22 2006-06-13 Genta Incorporated Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
WO2004012669A2 (en) 2002-08-01 2004-02-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
WO2005072097A2 (en) 2003-12-16 2005-08-11 University Of Massachusetts Toll-like receptor 9 modulators
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
WO2008104985A2 (en) 2007-03-01 2008-09-04 Rosetta Genomics Ltd. Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CN101031658A (zh) 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
JP2008000001A (ja) 2004-09-30 2008-01-10 Osaka Univ 免疫刺激オリゴヌクレオチドおよびその医薬用途
AU2005316503A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
US20070077231A1 (en) * 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
ES2544877T3 (es) 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
AU2007260779A1 (en) 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Polynucleotide therapy
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008076981A2 (en) 2006-12-15 2008-06-26 Board Of Regents, The University Of Texas System Inhibitors of ll-37- mediated immune reactivity to self nucleic acids
WO2009006141A2 (en) 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
US7879812B2 (en) 2007-08-06 2011-02-01 University Of Iowa Research Foundation Immunomodulatory oligonucleotides and methods of use therefor
JP2010536787A (ja) 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様受容体モジュレータ
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2009089401A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
EP2278979A4 (en) 2008-05-21 2012-09-26 Us Gov Health & Human Serv PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODESOXYNUCLEOTIDES
JP5415724B2 (ja) 2008-08-05 2014-02-12 長春華普生物技術有限公司 一種のオリゴヌクレオチド及びその応用
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
GB0906130D0 (en) 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
EP3087988A3 (en) 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US8053422B2 (en) 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides
EP2425001A4 (en) 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
US8987221B2 (en) 2009-06-01 2015-03-24 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
US20110070241A1 (en) * 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
EP2451974A2 (en) 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
WO2011159328A1 (en) 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
US20140378531A1 (en) 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CN102925485B (zh) 2012-11-09 2014-07-09 中国农业科学院兰州兽医研究所 双表达的aav重组病毒的制备方法
JP6106280B2 (ja) 2012-11-29 2017-03-29 Ｓｂｉバイオテック株式会社 阻害性オリゴヌクレオチド及びその使用
AU2014205544B2 (en) 2013-01-08 2018-07-12 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20140271550A1 (en) 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
US20170035864A1 (en) 2013-12-09 2017-02-09 Bullet Biotechnology, Inc. SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2015183943A2 (en) 2014-05-27 2015-12-03 Trustees Of Boston University Inhibitors of fibroproliferative disorders and cancer
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
AU2015339063A1 (en) 2014-10-31 2017-06-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted cytotoxic agents
WO2016130832A1 (en) 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
US20180110777A1 (en) 2015-03-19 2018-04-26 The Johns Hopkins University Method for regulation of telomere length
US10775367B2 (en) 2015-04-15 2020-09-15 Ji Hoon Lee Aptasensor and method of detecting target material
WO2016183370A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage
ES2781459T3 (es) 2015-07-29 2020-09-02 Ifom Fondazione St Firc Di Oncologia Molecolare Oligonucleótidos terapéuticos
US10653687B2 (en) 2015-11-18 2020-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compostions for treating rhabdomyolysis
WO2017111045A1 (en) 2015-12-25 2017-06-29 Sbi Biotech Co., Ltd. Tlr inhibitory oligonucleotides and their use
US10124062B2 (en) 2016-02-26 2018-11-13 The United States Of America As Represented By The Department Of Veterans Affairs Methods of treating, inhibiting and/or preventing an auditory impairment
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
KR102596343B1 (ko) 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)
JP2021502381A (ja) 2017-11-08 2021-01-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ウイルスベクター誘発性炎症反応を阻害するための組成物および方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182927A1 (en) * 1997-06-06 2011-07-28 Eyal Raz Inhibitors of DNA Immunostimulatory Sequence Activity
US20100069467A1 (en) * 2006-04-28 2010-03-18 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US20110236392A1 (en) * 2008-09-24 2011-09-29 O'neill Luke Anthony Composition and method for treatment of preterm labor
WO2010108035A1 (en) * 2009-03-18 2010-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for modulating toxic and proinflammatory effects
CN101712957A (zh) * 2009-11-25 2010-05-26 中国人民解放军第三军医大学第一附属医院 Toll样受体9阻断剂及应用
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
US20140004100A1 (en) * 2010-11-19 2014-01-02 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US20150238550A1 (en) * 2012-09-28 2015-08-27 The University Of North Carolina At Chapel Hill AAV Vectors Targeted to Oligodendrocytes
WO2014105870A1 (en) * 2012-12-27 2014-07-03 Sierra Sciences, Inc. Enhancing health in mammals using telomerase reverse transcriptase gene therapy
CN105597079A (zh) * 2016-01-11 2016-05-25 中国人民解放军第三军医大学第一附属医院 用于治疗银屑病的药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEGGY P. HO等: ""An immunomodulatory GpG Oligonucleotide for the treatment of autoimmunity via the Innate and Adaptive immune system"", J IMMUNOL, vol. 171, no. 9, pages 4920 - 4926 *
PETAR S. LENERT: ""Classification,Mechanisms of Action, and Therapeutic Applications of Inhibitory Oligonucleotides for Toll-Like Receptors(TLR) 7 and 9"", MEDIATORS OF INFLAMMATION, vol. 2010, pages 986596 *

Also Published As

Publication number Publication date
CN109451729B (zh) 2022-03-22
CN109451729A (zh) 2019-03-08
US11339396B2 (en) 2022-05-24
AU2017277647B2 (en) 2023-07-27
WO2017214378A1 (en) 2017-12-14
JP2022066336A (ja) 2022-04-28
US20240043849A1 (en) 2024-02-08
JP7394898B2 (ja) 2023-12-08
AU2023251424A1 (en) 2023-11-09
EP3468605A1 (en) 2019-04-17
AU2017277647A1 (en) 2018-12-13
US20190177731A1 (en) 2019-06-13
JP2019517266A (ja) 2019-06-24
US20190316151A1 (en) 2019-10-17
KR20190017872A (ko) 2019-02-20
JP7034951B2 (ja) 2022-03-14
EP3468605A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
AU2017277647B2 (en) Engineered viral vector reduces induction of inflammatory and immune responses
US12599678B2 (en) Methods and compositions for genomic integration
AU2017323629B2 (en) PD-1 homing endonuclease variants, compositions, and methods of use
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
JP2023036921A (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
AU2026203007A1 (en) Adeno-associated virus vector delivery of muscle specific microdystrophin to treat muscular dystrophy
KR20200085812A (ko) 바이러스 벡터-유도된 염증 반응을 억제하기 위한 조성물 및 방법
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
CN116348149A (zh) 用于肌营养不良症的腺相关病毒载体递送
KR20180034467A (ko) L-dopa의 전신 합성 및 조절
US20030166191A1 (en) Bistable genetic toggle switch
CN115867295A (zh) 用于靶向hpv感染细胞的组合物和方法
CN112867798A (zh) 用于治疗半乳糖血症的基因疗法
KR20240021765A (ko) 근이영양증 치료를 위한 재조합 aav 벡터의 제조
CN115698332A (zh) 在单细胞水平上评估载体转导效率和/或特异性的方法
HK40107753A (en) Production of recombinant aav vectors for treating muscular dystrophy
CN117642509A (zh) 产生用于治疗肌营养不良的重组aav载体
RU2781083C2 (ru) Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1
HK40082332B (en) Tools and methods for using cell division loci to control proliferation of cells
HK40082332A (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
HK40091239A (en) Compositions and methods for targeting hpv-infected cells
EA051943B1 (ru) Доставка специфичного для мышц микродистрофина с помощью вектора на основе аденоассоциированного вируса для лечения мышечной дистрофии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220729

WD01 Invention patent application deemed withdrawn after publication